Mezzion Pharma Co Ltd
KOSDAQ:140410
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mezzion Pharma Co Ltd
Cash from Investing Activities
Mezzion Pharma Co Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mezzion Pharma Co Ltd
KOSDAQ:140410
|
Cash from Investing Activities
₩1.9B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Cash from Investing Activities
-₩71B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash from Investing Activities
-₩35.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash from Investing Activities
-₩159.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-3%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash from Investing Activities
-₩42.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-12%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cash from Investing Activities
₩16.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Mezzion Pharma Co Ltd
Glance View
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
See Also
What is Mezzion Pharma Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
1.9B
KRW
Based on the financial report for Dec 31, 2025, Mezzion Pharma Co Ltd's Cash from Investing Activities amounts to 1.9B KRW.
What is Mezzion Pharma Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-12%
The average annual Cash from Investing Activities growth rates for Mezzion Pharma Co Ltd have been -52% over the past three years , -12% over the past five years .
